| Maddelynne Hobbs, LCSW | |
|
5629 W 13100 S, Herriman, UT 84096-6921 | |
| (801) 349-9606 | |
| (801) 336-4106 |
| Full Name | Maddelynne Hobbs |
|---|---|
| Gender | Female |
| Speciality | Social Worker - Clinical |
| Location | 5629 W 13100 S, Herriman, Utah |
| Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1205522604 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 1041C0700X | Social Worker - Clinical | 11819217-3502 (Utah) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Maddelynne Hobbs, LCSW 5629 W 13100 S, Herriman, UT 84096-6921 Ph: (801) 349-9606 | Maddelynne Hobbs, LCSW 5629 W 13100 S, Herriman, UT 84096-6921 Ph: (801) 349-9606 |
News Archive
Roll Call reports that infighting over some unemployment benefits and a scheduled "fix" of Medicare physician payments has left Democratic congressional leaders at a "dramatic low" in their relationship. "And while publicly, House and Senate leaders refused to assign blame, the behind-the-scenes story was far different. The deadline for the benefits package had been looming for weeks.
Tiny particles of iron oxide could become tools for simultaneous tumor imaging and treatment, because of their magnetic properties and toxic effects against brain cancer cells. In mice, researchers from Emory University School of Medicine have demonstrated how these particles can deliver antibodies to implanted brain tumors, while enhancing tumor visibility via magnetic resonance imaging (MRI).
Synergenz BioScience, Inc., a leader in predictive risk stratification for smoking-related lung cancer, was awarded a research grant under the Federal Government's Qualifying Therapeutic Discovery Project (QTDP) program.
Exoskeletons - wearable devices used by workers on assembly lines or in warehouses to alleviate stress on their lower backs - may compete with valuable resources in the brain while people work, canceling out the physical benefits of wearing them, a new study suggests.
IDM Pharma, Inc. today announced follow-up results from the Phase 2 study of IDM-2101 showing that the product candidate was well tolerated, induced broadly specific cytotoxic T lymphocyte (CTL) responses, and showed a positive survival trend in HLA-A2 positive patients with non-small cell lung cancer (NSCLC) who were treated with IDM-2101, compared to a parallel external control group of HLA-A2 negative non-treated patients.
› Verified 9 days ago
Ms. Lora J Watkins, LCSW Clinical Social Worker Medicare: Accepting Medicare Assignments Practice Location: 14217 S Tempest Ridge Cir, Herriman, UT 84096 Phone: 152-010-6219 Fax: 844-903-2824 | |
Brittany Bitters, LCSW Clinical Social Worker Medicare: Not Enrolled in Medicare Practice Location: 5629 W 13100 S, Herriman, UT 84096 Phone: 801-349-9606 Fax: 801-336-4106 | |
Nicole Nielsen, Clinical Social Worker Medicare: Not Enrolled in Medicare Practice Location: 5269 W Brundisi Way, Herriman, UT 84096 Phone: 801-598-3306 | |
Julie Madsen, LCSW Clinical Social Worker Medicare: May Accept Medicare Assignments Practice Location: 5627 W 13100 S Ste B, Herriman, UT 84096 Phone: 801-520-5724 | |
Tiana Mccall, LCSW Clinical Social Worker Medicare: Not Enrolled in Medicare Practice Location: 15155 S Rose View Ln, Herriman, UT 84096 Phone: 435-619-9570 | |
Haley Todd, LCSW Clinical Social Worker Medicare: Not Enrolled in Medicare Practice Location: 5629 W 13100 S, Herriman, UT 84096 Phone: 801-349-9606 Fax: 801-336-4106 |